ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.
Strides Pharma Science Ltd scheduled a board meeting for July 31, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Strides Pharma Science Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required under SEBI regulations.
Strides Pharma Science announced its 35th Annual General Meeting on August 14, 2026. The company also shared its Annual Report for FY2025-26.
Strides Pharma Science Ltd has filed its shareholding pattern for the quarter ended June 30, 2026. This disclosure is a routine regulatory compliance requirement.
Strides Pharma Science has fixed July 31, 2026, as the record date for its final dividend. The dividend is proposed at ₹5 per equity share.